• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics Product Image

Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics

  • Published: July 2013
  • Region: Global
  • 1064 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott Japan
  • AstraZeneca
  • Cypress Bioscience
  • ImmunoGen
  • Nektar Therapeutics
  • Schering-Plough
  • MORE

The Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in M&A dealmaking

2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2009
2.3.1. Japanese M&A accelerates
2.3.2. Option to acquire the new acquisition?
2.3.3. Case study 1: Cephalon – Ception
2.3.4. Case study 2: HertArt Aps – Vitrolife
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.5.1. M&A as an alternative to IPO
2.6. Partnering deals with M&A component
2.6.1. Partnering as a precursor to M&A
2.6.1.a. Case study 3: Celgene – VentiRx Pharmaceuticals, Oct 2012
2.6.2. Equity as part of partnering deal
2.6.2.a. Case study 4: BioMarin – Catalyst Pharma Partners, Oct 2012
2.6.2.b. Case study 5: Pfizer – Clovis Oncology , June 2011
2.6.2.c. Case study 6: Tesaro – OPKO Health, December 2010
2.6.3. Conversion of partnership to acquisition
2.6.4. But M&A is not always the route followed
2.7. Bigpharma mega mergers – are we at the end of the road?
2.7.1. Growth of Johnson & Johnson through M&A
2.7.2. Growth of Pfizer through M&A
2.8. Accessing innovation through M&A
2.8.1. Bigpharma acquisitions of small companies
2.8.1.a. Case study 7: Abbott – Facet Biotechnology
2.8.1.b. Case study 8: Gilead Sceinces – Pharmasset
2.8.2. Medium and small biopharma – use of M&A
2.8.2.a. Case study 9: Allergan – MAP Pharmaceuticals
2.8.2.b. Case study 10: Reckitt Benckiser – Schiff Nutrition International
2.8.3. Using M&A to build a company
2.8.3.a. Case study 11: Shire – built from M&A
2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.8.3.c. Case study 13: Novartis – from pure pharma to half generic
2.8.4. Emergence of biotech-biotech mergers
2.8.4.a. Case study 14: Merger between Biogen and Idec
2.8.4.b. Case study 15: Amgen acquisition activity
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma

Chapter 3 – Overview of M&A deal structure

3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica – November 2012
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma – AkaRx – October 2007
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals – Callisto Pharmaceuticals – July 2012

Chapter 4 – Leading M&A deals

4.1. Introduction
4.2. Top M&A deals by value
4.3. Top merger deals
4.3. Most active M&A dealmakers
4.4. Bigpharma M&A deal activity

Chapter 5 – Bigpharma M&A deals

5.1. Introduction
5.2. How to use M&A deals
5.3. Bigpharma company M&A deal profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mylan
Novartis
Pfizer
Roche
Sanofi
Sanofi-Aventis
Shionogi
Shire
Stada
Takeda
Teva
UCB
Valeant
Warner Chilcott

Chapter 6 – M&A contracts directory

6.1. Introduction
6.2. Company A-Z
6.3. By industry sector
Academic
Animal Health
Bigbiotech
Bigpharma
Biotech
Consumer health
Drug delivery
Medical device
Diagnostic
Financial
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

The following appendices are available in a accompanying volume.

Appendices

Appendix 1 – Company A-Z
Appendix 2 – By industry sector
Academic
Agricultural
Animal Health
Big pharma
Big biotech
Biotech
Consumer health
Drug delivery
Medical device
Diagnostic
Financial
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
Appendix 3 – M&A dealmaking references
Appendix 4 – Resources
Appendix 5 – Deal type definitions
Appendix 6 – Example M&A contract document

TABLE OF FIGURES

Figure 1: Definition of merger and acquisition
Figure 2: Trends in M&A deal announcements, 2009-2013
Figure 3: M&A deals signed at each phase of development, 2009-2013
Figure 4: Key recent M&A trends – 2009 to present
Figure 5: Recent Japanese M&A
Figure 6: Recent ‘option to acquire’ deals
Figure 7: Situations where M&A can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 11: Equity investments converting to acquisitions
Figure 10: Johnson & Johnson’s growth through M&A
Figure 11: Pfizer’s growth through M&A since 2000
Figure 14: Shire’s M&A history
Figure 13: Amgen’s biotech-biotech acquisition trail
Figure 14: Private equity M&A activity, 2009-2013
Figure 15: Issues in implementing M&A agreements
Figure 16: Joint venture agreements, 2007-2013
Figure 17: Example joint ventures in the biopharma sector
Figure 18: Future trends in M&A in biopharma
Figure 19: Components of the acquisition deal structure
Figure 20: Components of the merger deal structure
Figure 18: Top M&A deals by value since 2009
Figure 24: Top merger deals by value since 2009
Figure 23: Most active M&A dealmakers Jan 2009- May 2013
Figure 24: Bigpharma – top 50 – M&A deals 2009 to mid 2013
Figure 25: Bigpharma M&A deal frequency - 2009 to mid 2013

Abbott Japan

Abbott Laboratories

Abraxis BioScience

ACADIA Pharmaceuticals

Acceleron Pharma

Achillion Pharmaceuticals

Adnexus Therapeutics

Adolor

AEterna Zentaris

Affymax

Agensys

Alfacell

Allergan

Ambit Biosciences

Amgen

Amylin Pharmaceuticals

Anacor Pharmaceuticals

Anesiva

Archemix

Ariad Pharmaceuticals

ArQule

Array Biopharma

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Atley Pharmaceuticals

Auriga Laboratories

Aventis

AVEO Pharmaceuticals

Barrier Therapeutics

Bayer

Biogen Idec

BioMarin Pharmaceuticals

BioMerieux

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Cardiome Pharma

Celgene

Cell Genesys

Cepheid

ChemoCentryx

Cornerstone Biopharma

Cortex Pharmaceuticals

Critical Therapeutics

Cubist Pharmaceuticals

CV Therapeutics

Cypress Bioscience

Cytokinetics

Daiichi Sankyo

DepoMed

Dey Pharma

DoctorDirectory

DOR BioPharma

Dyax

Dynavax Technologies

Eisai

Eli Lilly

Enanta Pharmaceuticals

Endo Pharmaceuticals

Exelixis

Facet Biotechnology

Forest Laboratories

Forest Pharmaceuticals

Galderma

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GTx

Hyperion Therapeutics

ImmunoGen

Immunomedics

Impax Laboratories

Incyte

Inspire Pharmaceuticals

InterMune

InVentiv Health

Ipsen

Ironwood Pharmaceuticals

Janssen Research & Development

KaloBios Pharmaceuticals

La Jolla Pharmaceutical

Macrogenics

MAP Pharmaceuticals

Maxygen

Medivation

Menarini

Merck and Co

Merck KGaA

Merck Sharpe & Dohme

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

MiddleBrook Pharmaceutical

Millennium

Mylan Laboratories

Nektar Therapeutics

Novartis

Novartis Consumer Health

Novo Nordisk

Nycomed

OncoGenex Pharmaceuticals

Optimer Pharmaceuticals

Orexigen Therapeutics

Ortho Biotech

Par Pharmaceutical

PDL BioPharma

Pfizer

PhotoMedex

Procter & Gamble

Procter & Gamble Pharmaceuticals

Purdue Pharma

Regeneron Pharmaceuticals

Rib-X Pharmaceuticals

Roche

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Santarus

Schering-Plough

Seattle Genetics

Serono

Sigma-Tau

Solvay

Somaxon Pharmaceuticals

Spectrum Pharmaceuticals

Strativa Pharmaceuticals

Sucampo Pharmaceuticals

Synta Pharmaceuticals

Takeda Pharmaceutical

TAP Pharmaceutical

Targacept

Tercica

Teva Pharmaceuticals

Tibotec

Transcept Pharmaceuticals

Ucyclyd Pharma

Valeant Pharmaceuticals

Veracyte

Vernalis

Vical

Victory Pharma

Warner Chilcott

Watson Pharmaceuticals

Wyeth

Xenoport

Zogenix

ZymoGenetics

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos